• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
Right Arrow Button IconLeft Arrow Button IconHome
Right Arrow Button IconNovartis

Novartis

lacks
Law
The immortal life of Henrietta Lacks lawsuits gets a bit shorter with Novartis settlement
By Brian Witte and The Associated PressFebruary 27, 2026
Entrepreneur and Cost Plus Drugs cofounder Mark Cuban (right) speaks with Andrew Nusca, editorial director of Fortune’s Brainstorm series, at a Brainstorm Tech dinner on Monday, Jan. 6, 2025, in Las Vegas.
Health
Mark Cuban once helped his college friend save almost $10,000 on prescriptions after a ‘horrific car accident’
By Lindsey LeakeJanuary 7, 2025
Swiss pharma giant Novartis says 30 pipeline drugs with ‘significant potential’ will drive long-term growth
Finance
Swiss pharma giant Novartis says 30 pipeline drugs with ‘significant potential’ will drive long-term growth
By AFPNovember 21, 2024
Fortune Global Forum 2024 Tuesday, November 12, 2024 New York, NY 12:05 PM – 1:20 PM LUNCH STRATEGY SESSIONS PIONEERING TECH THAT DELIVERS NEXT-GEN SOLUTIONS As technology advances, the need to bring new classes of products to customers in both agile and innovative ways becomes crucial. Escalating trade tensions, climate change, geopolitical turmoil, and labor disputes are also throwing traditional commercialization models into disarray. These conflicts are, in turn, putting pressure on production lines, supply chains, and infrastructure, with domino effects across industries and borders. To remain competitive, business leaders must navigate these new complexities in order to deliver everything from life-saving medications to consumer products on time–and at scale. In this session, we’ll learn how some companies have been able to deliver next gen solutions while meeting the demands of a changing marketplace. Presented by Novartis Discussion Leaders: Victor Bulto, President, U.S., Novartis Jennifer Nuckles, Chief Executive Officer, R-Zero Charles van der Steene, President, North America, Maersk Krish Venkataraman, President, Dataiku Moderator: Alex Wood Morton, Fortune Photograph by Michael O’Shea for Fortune
Conferences
From biopharma to real estate to shipping, top CEOs insist AI is worth the hype
By Jane ThierNovember 15, 2024
Pascal Soriot, chief executive officer of Astrazeneca Plc, arrives at the CEO council at the Great Hall of the People in Beijing, Chin
Success
Major investors say AstraZeneca boss is ‘massively underpaid’ on $21.5 million salary, despite earning more than double Novo Nordisk’s CEO
By Ryan HoggApril 10, 2024
Stock traders from various companies work in five circular and one semi-circular trading floor at the Frankfurt Stock Exchange.
Finance
Meet Europe’s answer to the ‘Magnificent 7’—the high-flying ‘Granolas’ that Goldman Sachs is betting will prosper in the continent’s flatlining economy
By Ryan HoggMarch 3, 2024
How to talk about a war at work: Sometimes the bravest stance is not taking a stance
Leadership
How to talk about a war at work: Sometimes the bravest stance is not taking a stance
By Peter VanhamNovember 29, 2023
The world’s 10 biggest pharmaceutical companies raked in over $700 billion in revenue in 2021
Finance
The world’s 10 biggest pharmaceutical companies raked in over $700 billion in revenue in 2021
By Paige McGlauflinAugust 15, 2022
Novartis CEO Vas Narasimhan
Leadership
Novartis to cut as many as 8,000 jobs under plan to save $1 billion by 2024
By Eric Pfanner and BloombergJune 29, 2022
Brainstorm Health 2020-Giovanni Caforio-Vas Narasimhan
Conferences
Will the pharmaceutical industry keep collaborating after COVID-19? Novartis and Bristol Myers Squibb CEOs say it has to
By David Z. MorrisJuly 7, 2020
Novartis CEO explains why the wait for a coronavirus vaccine is so long
Leadership
Novartis CEO explains why the wait for a coronavirus vaccine is so long
By McKenna MooreJune 2, 2020
Novartis Zolgensma Gene Therapy Sales
Newsletters
Why a drug that costs $2.1 million per dose is on a sales streak
By Sy MukherjeeJanuary 29, 2020
Novartis Amarin Cholesterol Drugs
Newsletters
Novartis’ $9.7 Billion Deal Sets off Heart Drug Wars
By Sy MukherjeeNovember 25, 2019
American Vasant Narasimhan, CEO of Swiss pharmaceutical and drug maker Novartis speaks during a conference at the Fortune Global Forum event in Paris on Nov. 18, 2019. (Photo by ERIC PIERMONT / AFP) (Photo by ERIC PIERMONT/AFP via Getty Images)
Finance
Novartis Bets Big on Cholesterol Drug With $9.7 Billion Buyout of Medicines Co.
By James Paton and BloombergNovember 25, 2019
Novartis Zolgensma brother scientists
Newsletters
The Fallout from Novartis’ Alleged Data Manipulation: Brainstorm Health
By Sy MukherjeeAugust 14, 2019
1
  • 1
  • 2
  • 3
  • 4
  • 5
5
Most Popular
Success
MacKenzie Scott alone accounted for one-third of America's $19.2 billion in megagifts last yearplaceholder alt text
By Sydney LakeJune 25, 2026
Big Tech
As Big Tech showers employees with perks to win the talent war, Nvidia built a nearly $5 trillion company by making people pay for their own lunchplaceholder alt text
By Marco Quiroz-GutierrezJuly 1, 2026
Success
Philanthropy leader at Warren Buffett and Bill Gates’ Giving Pledge says children of billionaires are pushing them to give their wealth away fasterplaceholder alt text
By Preston ForeJune 27, 2026
Fortune Secondary Logo
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • World's Most Admired Companies
  • See All Rankings
  • Lists Calendar
Sections
  • Finance
  • Fortune Crypto
  • Features
  • Leadership
  • Health
  • Commentary
  • Success
  • Retail
  • Mpw
  • Tech
  • Lifestyle
  • CEO Initiative
  • Asia
  • Politics
  • Conferences
  • Europe
  • Newsletters
  • Personal Finance
  • Environment
  • Magazine
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
  • Group Subscriptions
About Us
  • About Us
  • Press Center
  • Work At Fortune
  • Terms And Conditions
  • Site Map
  • About Us
  • Press Center
  • Work At Fortune
  • Terms And Conditions
  • Site Map
  • Facebook icon
  • Twitter icon
  • LinkedIn icon
  • Instagram icon
  • Pinterest icon

© 2026 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.